Uniqure announces dosing of first patient in phase i/ii clinical trial of amt-162 for the treatment sod1-als

Lexington, mass. and amsterdam, oct. 15, 2024 (globe newswire) -- uniqure n.v. (nasdaq: qure), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the first patient has been dosed in the phase i/ii clinical trial of amt-162 for the treatment of amyotrophic lateral sclerosis (als) caused by mutations in superoxide dismutase 1 (sod1), a rare, inherited and progressive motor neuron disease. episod1 is a phase i/ii multi-center, open-label trial being conducted in the united states with three dose-escalating cohorts assessing the safety, tolerability and exploratory signs of efficacy of amt-162 in individuals with sod1-als.
AMT Ratings Summary
AMT Quant Ranking